Snaking toward a universal antivenom
Scripps Research InstituteScripps Research scientists discovered antibodies that protect against a host of lethal snake venoms.
Scripps Research scientists discovered antibodies that protect against a host of lethal snake venoms.
Nerve cells in the brain demand an enormous amount of energy to survive and maintain their connections for communicating with other nerve cells.
An antibody in single-chain fragment variable (scFv) format that binds to the powerful opioid carfentanil was shown to reverse signs of carfentanil overdose in preclinical tests conducted by scientists at Scripps Research.
For people with alcohol use disorder (AUD), there is a constant, vicious cycle between changes to the brain and changes to behavior. AUD can alter signaling pathways in the brain; in turn, those changes can exacerbate drinking.
“COVID rebound,” in which evidence of the illness disappears and then returns days or weeks later, is surprisingly common—whether or not patients are given the antiviral Paxlovid.
While COVID-19 may be transitioning from a “pandemic” to an “endemic” phase, it remains critically important to continue tracking the virus in real-time.
Human immunodeficiency virus 1, more commonly known as HIV-1, is known for its uncanny ability to evade the immune system.
New tools developed at Scripps Research and UC San Diego are helping public health officials around the world get vital information about pathogen variants from wastewater.
Mining the world's most comprehensive drug repurposing collection for COVID-19 therapies, scientists have identified 90 existing drugs or drug candidates with antiviral activity against the coronavirus that's driving the ongoing global pandemic.
Fast-spreading variants of the COVID-19-causing coronavirus, SARS-CoV-2, carry mutations that enable the virus to escape some of the immune response created naturally or by vaccination.
A team led by scientists at Scripps Research has discovered a common molecular feature found in many of the human antibodies that neutralize SARS-CoV-2, the coronavirus that causes COVID-19.
LA JOLLA, CA--An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a Scripps Research analysis of public datasets on asymptomatic infections.
Scientists at Scripps Research, inspired by electric car batteries, have developed a battery-like system that allows them to make potential advancements for the manufacturing of medicines.
As co-leaders of an international collaboration, scientists at Scripps Research have discovered that tethering four antibodies together may be an effective strategy for neutralizing all types of influenza virus known to infect humans.
New insight into how cells sense blood pressure could present better targets for treating hypertension.
Scientists at Scripps Research and their collaborators have created microorganisms that may recapitulate key features of organisms thought to have lived billions of years ago, allowing them to explore questions about how life evolved.
Scientists investigating how the human immune system defends against malaria have uncovered a rare phenomenon: antibodies working together to bind to a vulnerable spot on the parasite.
Predictors of future diabetes and cardiovascular disease for a person with obesity can be found among their body's metabolites.
Benedict Gross, PhD, a professor emeritus of mathematics at Harvard University and former dean of Harvard College, has joined the Board of Directors at Scripps Research.
The prestigious award will support the Cravatt laboratory with $7.8 million over seven years.
Scientists at Scripps Research have discovered the role of an immune system double agent. This molecule, called USP18, can help curtail immune responses, but it can also open the door to bacterial infections, such as harmful listeria and staph infections.
Havran, a professor at Scripps Research and associate dean of the Skaggs Graduate School of Chemical and Biological Sciences, was recently named the 2018 Outstanding Mentor by the Society of Fellows, a postdoctoral organization at Scripps Research.
Two new studies by scientists at Scripps Research are bringing Ebola virus’s weaknesses into the spotlight, showing for the first time exactly how human and mouse antibodies can bind to the virus and stop infection—not only for Ebola virus, but for other closely related pathogens as well.
Scientists at Scripps Research have developed a urine diagnostic to detect the parasitic worms that cause river blindness, also called onchocerciasis, a tropical disease that afflicts 18 to 120 million people worldwide.
"In humans, being able to tweak levels of TTR degradation could act as a means of stopping TTR toxicity."
The study, published recently in Nature Communications, shows that a molecule in cells, called Rad52, repairs special kinds of damaged DNA that accumulate in some cancers.
New Scripps Research study offers guidance for more effective Ebola vaccines
Expertise encompasses cancer, immunotherapy and regenerative medicine
The research offers another approach for tackling diseases that have been considered "undruggable," including amyotrophic lateral sclerosis (ALS), muscular dystrophy, cystic fibrosis and certain cancers.
“The big takeaway here is that we have a new molecular target linked to alcohol addiction,” says Olivier George, PhD, associate professor at Scripps Research.
Collaboration will focus on switchable CAR-T therapies aimed primarily at solid tumors.
The microbiome may harbor a gene for drug resistance
Scripps Research scientists have solved a major problem in chemistry and drug development by using droplet-sized ‘miniecosystems’ to quickly see if a molecule can function as a potential therapeutic.
"This new method should allow us to explore a large ‘chemical space’ that had been essentially off-limits."
A new study by Scripps Research, published today in Nature Communications, suggests scientists could build better drugs by learning from bacteria-derived molecules called thiocarboxylic acids.
Dubbed “T-cell engaging bi-specific antibodies,” these cancer combatants attack malignant cells but leave healthy cells untouched.
The new tool opens the possibility of creating drugs that can be taken conveniently as pills to correct genetic diseases.
Gilead Sciences’ Chairman of the Board of Directors, John C. Martin, PhD, has joined the Board of Directors at The Scripps Research Institute.
Former film executive Sherry Lansing, who led Paramount and Fox motion picture studios, has been named to the Board of Directors at The Scripps Research Institute.
The technique makes use of tiny, three-dimensional ball-like aggregates of cells called spheroids.
The new research opens the door to studying common brain conditions such as autism, schizophrenia, addiction and Alzheimer’s disease under reproducible conditions in a dish.
Floyd Romesberg, PhD, professor at The Scripps Research Institute, has won the 2018 Royal Society of Chemistry (RSC) Bioorganic Chemistry Award for his ground-breaking contributions to the expansion of the genetic alphabet.
Researchers take a closer look at drug candidate for a devastating genetic illness.
Working with mobile technology and bioinformatics companies, STSI will lead integration of mobile apps and digital medical devices into the program to collect and analyze an unprecedented range and depth of health data.
The research points to a possible new role for proteins in sensory processing in some people with autism spectrum disorder.
With the new funding from the Gates Foundation, the Scripps Research team will expand their studies of neutralizing antibodies.
The Scripps Translational Science Institute (STSI) has received over $34 million in renewed funding from the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) to advance medical research and clinical care through genomic and digital technologies.
Scientists at The Scripps Research Institute are launching a pair of studies on genetic factors behind oxycodone and cocaine addiction and treatment.
Scientists at The Scripps Research Institute have identified a protein, called GPR68, that senses blood flow and tells small blood vessels called arterioles when to dilate.
This new insight may allow researchers to design drugs that improve immune responses to vaccines.